---
schema_version: "secwatch.filing_event.v1"
accession: "0001459839-23-000088"
form_type: "8-K"
ticker: "SIBN"
cik: "0001459839"
company_name: "SI-BONE, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:04:29.699228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SI-BONE Q2 revenue $33.3M (+30% YoY); raises FY 2023 revenue guidance to $132-134M

## Summary
- Record worldwide revenue $33.3M (+30% YoY); U.S. revenue $31.2M (+31% YoY).
- Net loss improved to $11.2M ($0.30 diluted loss) from $18.5M ($0.54) in Q2 2022.
- Adjusted EBITDA loss narrowed 59% to -$4.7M from -$11.5M.
- FY 2023 revenue guidance raised to $132-134M (prior $128-131M), implying 24-26% growth.
- Gross margin 81% vs 86% a year ago, impacted by product mix and higher depreciation.

## SEC filing metadata
- accession: 0001459839-23-000088
- form_type: 8-K
- ticker: SIBN
- cik: 0001459839
- company_name: SI-BONE, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1459839/000145983923000088/0001459839-23-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1459839/000145983923000088/sibn-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001459839-23-000088
- JSON: https://secwatch.observer/filing/0001459839-23-000088.json
- Plain text: https://secwatch.observer/filing/0001459839-23-000088.txt

## Key facts
- Earnings Releases
  SI-BONE, Inc. reported the quarter ended June 30, 2023 results: revenue $33.3 million, net income $11.2 million, or $0.30 per diluted share, EPS $0.30 per diluted share. Guidance raised.
  - Period: the quarter ended June 30, 2023
  - Revenue: $33.3 million
  - Net income: $11.2 million, or $0.30 per diluted share
  - EPS: $0.30 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2023. Recent Highlights • Record worldwide revenue of $33.3 million for the second quarter 2023, representing approximately 30% growth over the corresponding period in 2022 • Record U.S. revenue of $31.2 million for the second quarter 2023,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1459839/000145983923000088/0001459839-23-000088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.